Influenza A(H5N1) Virus Subunit Vaccine Administered with CaPNP Adjuvant Induce High Virus Neutralization Antibody Titers in Mice
The highly pathogenic avian influenza H5N1 virus continues to spread globally in domestic poultry with sporadic transmission to humans. The possibility for its rapid transmission to humans raised global fears for the virus to gain capacity for human-to-human transmission to start a future pandemic. Through direct contact with infected poultry, it caused the largest number of reported cases of severe disease and death in humans of any avian influenza strains. For pandemic preparedness, use of safe and effective vaccine adjuvants and delivery systems to improve vaccine efficacy are considered imperative. We previously demonstrated CaPtivate’s proprietary CaP nanoparticles (CaPNP) as a potent vaccine adjuvant/delivery system with ability to induce both humoral and cell-mediated immune responses against many viral or bacterial infections. In this study, we investigated the delivery of insect cell culture-derived recombinant hemagglutinin protein (HA) of A/H5N1/Vietnam/1203/2004 virus using CaPNP. We evaluated the vaccine immunogenicity in mice following two intramuscular doses of 3 μg antigen combined with escalating doses of CaPNP. Our data showed CaPNP-adjuvanted HA(H5N1) vaccines eliciting significantly higher IgG, hemagglutination inhibition, and virus neutralization titers compared to non-adjuvanted vaccine. Among the four adjuvant doses that were tested, CaPNP at 0.24% final concentration elicited the highest IgG and neutralizing antibody titers. We also evaluated the inflammatory response to CaPNP following a single intramuscular injection in guinea pigs and showed that CaPNP does not induce any systemic reaction or adverse effects. Current data further support our earlier studies demonstrating CaPNP as a safe and an effective adjuvant for influenza vaccines.
KEY WORDSCaP nanoparticles adjuvant A/H5N1 pandemic influenza
This study was supported by BioSante Pharmaceuticals Inc. and by CaPtivate Pharmaceuticals LLC. The authors thank BioCon Inc. (Rockville, MD) small animal facility staff for performing the animal studies, Battelle scientists for performing HAI and MN assays, and IITRI facility staff and scientists for performing the acute toxicity studies.
Compliance with Ethical Standards
All immunization studies were performed at BioCon Inc. (Rockville, MD) in the company’s Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)-accredited Laboratory Animal Research Facility. Animals were housed according to Office of Laboratory Animal Welfare (OLAW) and AAALAC Guidelines. All animal experiments and related protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of BioCon. Experiments were conducted in accordance with the guidelines set out by the AAALAC. Acute toxicity studies were performed separately with contract to IIT Research Institute (IITRI-Chicago, IL.) and in accordance with U.S. Food and Drug Administration (FDA) Good Laboratory Practice (GLP) Regulations as set forth in the Code of Federal Regulations.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.WHO consultation and information meeting on the composition of influenza virus vaccines for the northern hemisphere 2016–2017. Available at: www.who.int/influenza/vaccines/virus/recommendations/consultation201602/en/index2.html
- 2.NIAID Strategic Plan for Research on Vaccine Adjuvants. Available at: https://rsc.niaid.nih.gov/sites/default/files/NIAID-StrategicPlanVaccineAdjuvants.pdf
- 3.WHO, Cumulative number of confirmed human cases for H5N1, 2003–2017 http://www.who.int/influenza/human_animal_interface/2017_06_15_tableH5N1-corrected.pdf?ua=1
- 7.Editorial-The Lancet. Plotting a route to a universal influenza vaccine. Lancet Infect Dis 2018;18: 475.Google Scholar
- 10.WHO, “Global pandemic influenza action plan to increase vaccine supply,” Tech. Rep. WHO/IVB/06.13; WHO/CDS/EPR/GIP/2006.1, WHO, Geneva, 2006, http://whqlibdoc.who.int/hq/2006/WHO_IVB_06.13_eng.pdf?ua=1
- 13.HHS, Office of ASPR, Medical Countermeasures (MCM). Pandemic Influenza: Current vaccine and adjuvant stockpiles. Available at: https://www.medicalcountermeasures.gov/media/35695/cioce_current_vaccine_and_adjuvant_stockpiles.pdf
- 17.Vesikari T, Kirstein J, Devota Go G, Leav B, Ruzycky ME, Isakov L, et al. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Lancet Respir Med. 2018;6:345–56.PubMedCrossRefGoogle Scholar
- 18.van den Brand JMA, Kreijtz JHCM, Bodewes R, Stittelaar KJ, van Amerongen G, Kuiken T, et al. Efficacy of vaccination with different combinations of MF59-Adjuvanted and Nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J Virology. 2011;85:2851–8.PubMedCrossRefGoogle Scholar
- 19.European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation) Stockholm: ECDC; September 2012, Stockholm, Sweden, ISBN 978–92–9193-388-4. (VAESCO report).Google Scholar
- 20.Reilly J. Final Report of National Narcolepsy Study Steering Committee, Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010. April 476 19, 2012. Available at: https://health.gov.ie/wp-content/uploads/2014/03/Final_Report_of_National_Narcolepsy_Study_Steering_Committee.pdf. Accessed February 9, 2015 and Jan 6, 2019.
- 27.He Q, Mitchell A, Johnson SL, Wagner-Bartak C, Morcol T, Bell SJD. Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol. 2000;6:899–903.Google Scholar
- 28.He Q, Mitchell AR, Johnson SL, Morcol T, Bell SJD. Calcium phosphate particles induced mucosal immunity and protection against herpes simplex V2. Clin Diagnos Lab Immunol. 2002;9:1021–4.Google Scholar
- 32.Karam HM, Shaaban EA, Mohamed AF, Zaki HF, Kenawy SA. New approach for improving production of Naja Haje snake antivenom. Int J Science Res Publications. 2015;XXXX:5.Google Scholar
- 33.CaPtivate Pharmaceuticals Reports Data from Influenza A/H1N1 2009 Pandemic virus vaccine studies funded by NIAID/NIH preclinical services program: CaP nanoparticle adjuvant significantly improves vaccine efficacy. Available at: http://www.ireachcontent.com/news-releases/captivate-pharmaceuticals-reports-data-from-influenza-ah1n1-2009-pandemic-virus-vaccine-studies-funded-by-niaidnih-preclinical-services-program-671631134.html
- 35.Morçol T, Nagappan P, Nerenbaum L, Mitchell A, Bell, SJD. (2006) Particulate Drug Delivery Systems for Protein Drugs: An Overview of Non-invasive Insulin Delivery Using Calcium Phosphate Particle Technology in: Handbook of Particulate Drug Delivery, Chapter 11, Kumar, R.M.N.V. (Ed.), American Scientific Publishers, Stevenson Ranch, CA.Google Scholar
- 38.O’Hagan DT, Tsai T, Reed S. Emulsion based adjuvants for improved influenza vaccine in: influenza vaccines for the future. Del Giudice G, Rappuoli R (Eds). Springer; Basel AG. In: 327–358; 2011.Google Scholar
- 40.Leroux-Roels I, Roman F, Forgus S, Maes C, de Boever F, Dramé M, et al. Priming with AS03-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomized extension of a double-blind randomized primary study. Vaccine. 2010;28:849–57.PubMedCrossRefGoogle Scholar
- 42.Seasonal Flu Vaccine Fluad Approved by FDA. Deceber 02, 2015. Available at: https://www.pharmacytimes.com/product-news/seasonal-flu-vaccine-fluad-approved-by-fda.
- 43.BioSante Pharmaceuticals, Inc. Announces CaP Nanotechnology Product Development-New Product. February 5, 2004. Available at: https://www.azonano.com/article.aspx?ArticleID=477
- 53.Ph.Eur. 6.ed. Vaccines for human use, pp. In: 3971; 2009.Google Scholar